Literature DB >> 2334641

Molecular characterization of beta-thalassaemia in 174 Greek patients with thalassaemia major.

C Kattamis1, H Hu, G Cheng, A L Reese, J M Gonzalez-Redondo, A Kutlar, F Kutlar, T H Huisman.   

Abstract

The mutations producing beta-thalassaemia in 174 Greek patients with thalassaemia major were investigated by dot-blot hybridization of oligonucleotide probes to genomic DNA amplified by the polymerase chain reaction procedure, by direct sequencing of amplified DNA, and by gene mapping. beta-thalassaemia in Greeks was found to be very heterogeneous at the molecular level as 17 different mutations were observed: 86.6% of the beta-thalassaemic genes, however, could be identified with five probes: IVS-I-110 (G----A) (42.5%), codon 39 (C----T) (17%), IVS-I-1 (G----A) (13.2%), IVS-I-6 (T----C) (7.2%) and IVS-II-745 (C----G) (6.9%). Several mutations which had not previously been reported in the Greek population and which occurred at an incidence of 2% or lower were observed in this study. The information obtained will facilitate the prenatal diagnosis of beta-thalassaemia in Greece.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334641     DOI: 10.1111/j.1365-2141.1990.tb02593.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  The molecular basis of beta-thalassemia in Turkey.

Authors:  A N Başak; H Ozçelik; A Ozer; A Tolun; M Aksoy; L Ağaoğlu; F Ridolfi; L Ulukutlu; N Akar; A Gürgey
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

2.  Beta-thalassaemia: molecular pathogenesis and clinical variability.

Authors:  A E Kulozik
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

3.  Fetal hemoglobin in normal adults and beta-thalassemia heterozygotes.

Authors:  A Kutlar; F Kutlar; L G Gu; S M Mayson; T H Huisman
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

Review 4.  PCR-SSCP: a method for the molecular analysis of genetic diseases.

Authors:  V Konstantinos Kakavas; Kakavas V Konstantinos; Panagiotis Plageras; Plageras Panagiotis; T Antonios Vlachos; Vlachos T Antonios; Agelos Papaioannou; Papaioannou Agelos; V Argiris Noulas; Noulas V Argiris
Journal:  Mol Biotechnol       Date:  2007-10-13       Impact factor: 2.695

5.  Epidemiological profile of common haemoglobinopathies in Arab countries.

Authors:  Hanan A Hamamy; Nasir A S Al-Allawi
Journal:  J Community Genet       Date:  2012-12-08

6.  The great heterogeneity of thalassemia molecular defects in Sicily.

Authors:  A Giambona; P Lo Gioco; M Marino; I Abate; R Di Marzo; M Renda; F Di Trapani; F Messana; S Siciliano; P Rigano
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

7.  Molecular characterization of beta-thalassemia in Azerbaijan.

Authors:  M A Cürük; G T Yüregir; C D Asadov; T Dadasova; L H Gu; E Baysal; Y C Gu; M L Ribeiro; T H Huisman
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

8.  Identification of the four most common beta-globin gene mutations in Greek beta-thalassemic patients and carriers by PCR-SSCP: advantages and limitations of the method.

Authors:  Konstantinos V Kakavas; Argiris Noulas; Christos Chalkias; Christos Hadjichristodoulou; Ioannis Georgiou; Elena Georgatsou; Sophia Bonanou
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

9.  Sickle cell anemia, sickle cell beta-thalassemia, and thalassemia major in Albania: characterization of mutations.

Authors:  E Boletini; M Svobodova; V Divoky; E Baysal; M A Cürük; A J Dimovski; R Liang; A D Adekile; T H Huisman
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

Review 10.  β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint.

Authors:  Vincenzo De Sanctis; Christos Kattamis; Duran Canatan; Ashraf T Soliman; Heba Elsedfy; Mehran Karimi; Shahina Daar; Yasser Wali; Mohamed Yassin; Nada Soliman; Praveen Sobti; Soad Al Jaouni; Mohamed El Kholy; Bernadette Fiscina; Michael Angastiniotis
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-02-20       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.